We provide evidence that BTK inhibition downregulates 14q32 cluster miRNAs and upregulates PTEN in CLL and DLBCL cell lines, an observation that is strengthened by our findings in patient-derived primary CLL cells treated with BTK inhibitors in vitro (Fig. 3c, d) and in samples from patients undergoing ibrutinib therapy in the clinic. This evidence concerns the gene PTEN and B-cell chronic lymphocytic leukemia.